OHR Pharmaceutical Inc.

Financials

v3.7.0.1
Consolidated Balance Sheets (Unaudited) - USD ($)
Jun. 30, 2017
Sep. 30, 2016
CURRENT ASSETS    
Cash and cash equivalents $ 18,079,406 $ 12,546,890
Prepaid expenses and other current assets 436,607 738,118
Total Current Assets 18,516,013 13,285,008
EQUIPMENT, net 79,806 198,631
OTHER ASSETS    
Security deposit 12,243 12,243
Intangible assets, net 14,369,747 15,208,219
Goodwill 740,912 740,912
TOTAL ASSETS 33,718,721 29,445,013
CURRENT LIABILITIES    
Accounts payable and accrued expenses 5,435,997 4,394,068
Notes payable 158,645 87,798
Total Current Liabilities 5,594,642 4,481,866
Long-term liability 150,000  
TOTAL LIABILITIES 5,744,642 4,481,866
STOCKHOLDERS' EQUITY    
Preferred stock, Series B; 6,000,000 shares authorized, $0.0001 par value, 0 shares issued and outstanding, respectively
Common stock; 180,000,000 shares authorized, $0.0001 par value, 56.211,428 and 32,076,396 shares issued and outstanding, respectively 5,621 3,207
Additional paid-in capital 130,812,624 109,237,551
Accumulated deficit (102,844,166) (84,277,611)
Total Stockholders' Equity 27,974,079 24,963,147
TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY $ 33,718,721 $ 29,445,013
v3.7.0.1
Consolidated Statements of Operations (Unaudited) - USD ($)
3 Months Ended 9 Months Ended
Jun. 30, 2017
Jun. 30, 2016
Jun. 30, 2017
Jun. 30, 2016
OPERATING EXPENSES        
General and administrative $ 1,404,287 $ 1,664,882 $ 4,554,704 $ 5,849,374
Research and development 2,233,388 5,637,602 13,158,460 11,757,741
Depreciation and amortization 288,976 296,143 879,286 889,959
Gain on Settlement of Accounts Payable (70,757)   (70,757) (710,264)
OPERATING LOSS 3,855,894 7,598,627 18,521,693 17,786,810
OTHER INCOME (EXPENSE)        
Change in fair value of contingent consideration   (104,844)   (1,356,770)
Other income 5,441   5,441 3,419
Interest income (expense), net (50,376) 3,730 (50,303) 10,099
Total Other Income (Expense) (44,935) (101,114) (44,862) (1,343,252)
LOSS FROM OPERATIONS BEFORE INCOME TAXES (3,900,829) (7,699,741) (18,566,555) (19,130,062)
NET LOSS $ (3,900,829) $ (7,699,741) $ (18,566,555) $ (19,130,062)
BASIC AND DILUTED LOSS PER SHARE (in dollars per share) $ (0.07) $ (0.24) $ (0.45) $ (0.61)
WEIGHTED AVERAGE NUMBER OF SHARES OUTSTANDING:        
BASIC AND DILUTED (in shares) 53,986,150 31,501,540 40,916,570 31,126,656
v3.7.0.1
Consolidated Statements of Cash Flows (Unaudited) - USD ($)
9 Months Ended
Jun. 30, 2017
Jun. 30, 2016
OPERATING ACTIVITIES    
Net loss $ (18,566,555) $ (19,130,062)
Adjustments to reconcile net loss to net cash used by operating activities:    
Common stock issued for services 783,842 1,237,064
Stock option expense 1,256,644 2,335,197
Change in fair value of contingent consideration   1,356,770
Depreciation 40,814 48,012
Amortization of intangible assets 838,472 841,947
Gain on settlement of accounts payable (70,757) (710,264)
Gain on sale of property and equipment (5,441)  
Changes in operating assets and liabilities    
Prepaid expenses and deposits 444,036 322,544
Accounts payable and accrued expenses 1,262,686 2,745,372
Net Cash Used in Operating Activities (14,016,259) (10,953,420)
INVESTING ACTIVITIES    
Purchase of property and equipment (4,833) (13,306)
Sale of property and equipment 88,285  
Net Cash Used in Investing Activities 83,452 (13,306)
FINANCING ACTIVITIES    
Proceeds from issuance of common stock for cash, net 19,537,001  
Proceeds from warrants exercised for cash 118,801 26,041
Repayments of short-term notes payable (190,479) (132,918)
Net Cash Provided by/(Used in) Financing Activities 19,465,323 (106,877)
NET CHANGE IN CASH AND CASH EQUIVALENTS 5,532,516 (11,073,603)
CASH AND CASH EQUIVALENTS AT BEGINNING OF PERIOD 12,546,890 28,697,323
CASH AND CASH EQUIVALENTS AT END OF PERIOD 18,079,406 21,881,370
CASH PAID FOR:    
Interest 5,107 4,262
NON CASH FINANCING ACTIVITIES:    
Settlement of contingent consideration   2,061,136
Financing of insurance premiums through issuance of short term notes $ 261,326 $ 215,810